skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Brain penetrant small molecule 18 F-GnRH receptor (GnRH-R) antagonists: Synthesis and preliminary positron emission tomography imaging in rats

Authors:
ORCiD logo; ORCiD logo; ; ; ; ; ; ;
Publication Date:
Sponsoring Org.:
USDOE
OSTI Identifier:
1324335
Grant/Contract Number:
SL0002061
Resource Type:
Journal Article: Publisher's Accepted Manuscript
Journal Name:
Nuclear Medicine and Biology
Additional Journal Information:
Journal Volume: 43; Journal Issue: 8; Related Information: CHORUS Timestamp: 2017-10-04 16:43:17; Journal ID: ISSN 0969-8051
Publisher:
Elsevier
Country of Publication:
United Kingdom
Language:
English

Citation Formats

Olberg, Dag E., Bauer, Nadine, Andressen, Kjetil W., Hjørnevik, Trine, Cumming, Paul, Levy, Finn O., Klaveness, Jo, Haraldsen, Ira, and Sutcliffe, Julie L.. Brain penetrant small molecule 18 F-GnRH receptor (GnRH-R) antagonists: Synthesis and preliminary positron emission tomography imaging in rats. United Kingdom: N. p., 2016. Web. doi:10.1016/j.nucmedbio.2016.05.003.
Olberg, Dag E., Bauer, Nadine, Andressen, Kjetil W., Hjørnevik, Trine, Cumming, Paul, Levy, Finn O., Klaveness, Jo, Haraldsen, Ira, & Sutcliffe, Julie L.. Brain penetrant small molecule 18 F-GnRH receptor (GnRH-R) antagonists: Synthesis and preliminary positron emission tomography imaging in rats. United Kingdom. doi:10.1016/j.nucmedbio.2016.05.003.
Olberg, Dag E., Bauer, Nadine, Andressen, Kjetil W., Hjørnevik, Trine, Cumming, Paul, Levy, Finn O., Klaveness, Jo, Haraldsen, Ira, and Sutcliffe, Julie L.. 2016. "Brain penetrant small molecule 18 F-GnRH receptor (GnRH-R) antagonists: Synthesis and preliminary positron emission tomography imaging in rats". United Kingdom. doi:10.1016/j.nucmedbio.2016.05.003.
@article{osti_1324335,
title = {Brain penetrant small molecule 18 F-GnRH receptor (GnRH-R) antagonists: Synthesis and preliminary positron emission tomography imaging in rats},
author = {Olberg, Dag E. and Bauer, Nadine and Andressen, Kjetil W. and Hjørnevik, Trine and Cumming, Paul and Levy, Finn O. and Klaveness, Jo and Haraldsen, Ira and Sutcliffe, Julie L.},
abstractNote = {},
doi = {10.1016/j.nucmedbio.2016.05.003},
journal = {Nuclear Medicine and Biology},
number = 8,
volume = 43,
place = {United Kingdom},
year = 2016,
month = 8
}

Journal Article:
Free Publicly Available Full Text
Publisher's Version of Record at 10.1016/j.nucmedbio.2016.05.003

Citation Metrics:
Cited by: 1work
Citation information provided by
Web of Science

Save / Share:
  • Purpose: To establish whether {sup 18}F-3'-deoxy-3'-fluoro-L-thymidine ({sup 18}F-FLT) can monitor changes in cellular proliferation of non-small-cell lung cancer (NSCLC) during radical chemo-radiotherapy (chemo-RT). Methods and Materials: As part of a prospective pilot study, 5 patients with locally advanced NSCLC underwent serial {sup 18}F-FLT positron emission tomography (PET)/computed tomography (CT) scans during treatment. Baseline {sup 18}F-FLT PET/CT scans were compared with routine staging {sup 18}F-FDG PET/CT scans. Two on-treatment {sup 18}F-FLT scans were performed for each patient on Days 2, 8, 15 or 29, providing a range of time points for response assessment. Results: In all 5 patients, baseline lesional uptakemore » of {sup 18}F-FLT on PET/CT corresponded to staging {sup 18}F-FDG PET/CT abnormalities. {sup 18}F-FLT uptake in tumor was observed on five of nine (55%) on-treatment scans, on Days 2, 8 and 29, but not Day 15. A 'flare' of {sup 18}F-FLT uptake in the primary tumor of one case was observed after 2 Gy of radiation (1.22 x baseline). The remaining eight on-treatment scans demonstrated a mean reduction in {sup 18}F-FLT tumor uptake of 0.58 x baseline. A marked reduction of {sup 18}F-FLT uptake in irradiated bone marrow was observed for all cases. This reduction was observed even after only 2 Gy, and all patients demonstrated a complete absence of proliferating marrow after 10 Gy. Conclusions: This proof of concept study indicates that {sup 18}F-FLT uptake can monitor the distinctive biologic responses of epithelial cancers and highly radiosensitive normal tissue changes during radical chemo-RT. Further studies of {sup 18}F-FLT PET/CT imaging during therapy may suggest that this tracer is useful in developing response-adapted RT for NSCLC.« less
  • Positron emission tomography (PET) and /sup 11/C-labeled pimozide were used to study the dopaminergic (DA) receptor sites in the human striatum by comparing the latter with the cerebellum, which lacks DA receptors. Although /sup 11/C-pimozide concentration was not different in these two brain structures up to 53 minutes after IV injection (thus implying large nonspecific binding), a significant retention of radioactivity in striatum relative to cerebellum was found in controls but not in subjects pretreated with the unlabeled competitor haloperidol. This suggests that the striatal retention seen in controls was due to specific binding of /sup 11/C-pimozide to DA receptormore » sites, whereas prior occupation of the receptor sites by the unlabeled competitor was achieved in pretreated subjects.« less
  • Two substituted benzamides, FLB 524 and raclopride, were labeled with C and examined for their possible use as ligands for positron emission tomography (PET) scan studies on dopamine-2 (D-2) receptors in the brains of monkeys and healthy human subjects. Both ligands allowed the in vivo visualization of D-2 receptor binding in the corpus striatum caudate nucleus/putamen complex in PET-scan images. ( C)Raclopride showed a high ratio of specific striatal to nonspecific cerebellar binding, and the kinetics of binding of this ligand made it optimal for PET studies. The in vivo binding of ( C)raclopride in the striatum of cynomolgus monkeysmore » was markedly reduced by displacement with haloperidol. In healthy human subjects, ( C)raclopride binding in the caudate nucleus/putamen was 4- to 5-fold greater than nonspecific binding in the cerebellum. In comparison with previously available ligands for PET-scan studies on central dopamine receptors in man, ( C)raclopride appears to be advantageous with regard to (i) specificity of binding to D-2 receptors, (ii) the high ratio between binding in dopamine-rich (caudate, putamen) and dopamine-poor (cerebellum) human brain regions, and (iii) rapid association and reversibility of specific binding.« less
  • The binding of an iodinated benzodiazepine (BZ) radioligand has been characterized, particularly in regard to its potential use as a neuroreceptor brain imaging agent with SPECT (Single Photon Emission Computed Tomography). Ro16-0154 is an iodine-containing BZ antagonist and a close analog of Ro15-1788. In tissue homogenates prepared from human and monkey brain, the binding of {sup 125}I-labeled Ro16-0154 was saturable, of high affinity, and had high ratios of specific to non-specific binding. Physiological concentrations of NaCl enhanced specific binding approximately 15% compared to buffer without this salt. Kinetic studies of association and dissociation demonstrated a temperature dependent decrease in affinitymore » with increasing temperature. Drug displacement studies confirmed that {sup 125}I-Ro16-0154 binds to the central type BZ receptor: binding is virtually identical to that of {sup 3}H-Ro15-1788 except that {sup 125}I-Ro16-0154 shows an almost 10 fold higher affinity at 37{degree}C. These in vitro results suggest that {sup 123}I-labeled Ro16-0154 shows promise as a selective, high affinity SPECT probe of the brain's BZ receptor.« less
  • Two patients with cerebral gliomas were studied with 18F-fluorophenylalanine, newly synthesized by the electrophilic substitution reaction, using positron emission tomography. The tracer accumulated markedly in the tumor lesion and delineated the extent of the lesion. This new tracer will be promising in the diagnosis of gliomas.